Trends in cardiovascular mortality of cancer patients in the US over two decades 1999‐2019

Abstract

Background Cancer is the second most common cause of death globally after cardiovascular disease, and cancer patients are at an increased risk of CV death. This recognition has led to publication of cardio‐oncological guidelines and to the widespread adoption of dedicated cardio‐oncology services in many institutes. However, it is unclear whether there has been a change in the incidence of CV death in cancer patients. Methods and Results Using Centers for Disease Control and Prevention Wide‐Ranging, Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death dataset, we determined national trends in age‐standardised mortality rates attributed to cardiovascular diseases in patients with and without cancer, from 1999 to 2019, stratified by cancer type, age, gender, race, and place of residence (state and urbanisation status). Among more than 17.8 million cardiovascular deaths in the United States, 13.6% were patients with a concomitant cancer diagnosis. During the study period, among patients with cancer, the age‐adjusted mortality rate dropped by 52% (vs 38% in patients with no cancer). In cancer patients, age‐adjusted mortality rate dropped more significantly among patients with gastrointestinal, breast, and prostate malignancy than among patients with haematological malignancy (59%‐63% vs. 41%). Similar reduction was observed in both genders (53%‐54%), but more prominent reduction was observed in older patients and in those living in metro areas. Conclusions Our findings emphasise the role of multidisciplinary management of cancer patients. Widespread adoption of cardio oncology services have the potential to impact the inherent risk of increased CV mortality in both cancer patients and survivors.

Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 and 2017

“…We observed a decrease in hospital CV mortality trend in patients with hematological malignancy, this is in accordance with our previous work that reported a decreasing trend of ageadjusted cardiovascular mortality in patients with hematological malignancies 29 , this may reflect improvement in the treatment of CV diseases, adoption of cardio-oncology guidelines and services and improved awareness to the increased risk of this population.…”

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan

“…With recent improvements in diagnostics and therapeutics in various fields, including cardiology and urology, the resultant increase in the number of survivors from individual diseases and aging will further augment the subsequent risk of developing cardiovascular and noncardiovascular complications. In particular, patients with cancer generally have an increased risk for CVD ( 50 – 52 ), and the development of a better healthcare system is urgently needed in order to provide multidisciplinary clinical management and appropriate cardiovascular care (“onco-cardiology”) to patients with cancer.…”

Trends in CV mortality among patients with known mental and behavioral disorders in the US between 1999 and 2020

“…In this retrospective study, the number of deaths and crude-and age-adjusted mortality rates between 1 January 1999 and 31 December 2020 were obtained from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death dataset. The method we used was previously described when studying a different population (16).…”